Peptide questions · CagriSema
CagriSema side effects: what studies and users report
Reviewed Evidence: EstablishedPublished by PepVault
The side effects most commonly reported for CagriSema are nausea, vomiting and diarrhea, among 5 the library lists; the library’s evidence on it includes controlled trials in people.
Its safety note opens: CagriSema has no label yet.
What is commonly reported with CagriSema
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 24) |
|---|---|
| Nausea | 21: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 17 more |
| Vomiting | 18: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 14 more |
| Diarrhea | 20: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 16 more |
| Constipation | 13: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 9 more |
| Abdominal pain | 7: Semaglutide (oral), Tirzepatide, Retatrutide, Dulaglutide and 3 more |

Model. Individual results vary.
Which CagriSema side effects the metabolic & GLP-1 group shares
Across the 25 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (22 of 25), diarrhea (21 of 25), vomiting (19 of 25) and constipation (14 of 25). Every effect on CagriSema’s list also appears for at least one other metabolic & GLP-1 compound, so nothing on it is CagriSema’s own.
What the CagriSema safety notes say
The library’s safety note
CagriSema has no label yet. In REDEFINE 1, GI side effects (nausea, vomiting, diarrhea, constipation, abdominal pain) affected 79.6% on CagriSema vs 39.9% on placebo, mainly passing and mild to moderate; in REDEFINE 2 (type 2 diabetes), 72.5% vs 34.4%. Its semaglutide half carries the semaglutide labels' warnings: the boxed warning for thyroid C-cell tumors seen in rodents (human relevance not determined; the labels rule it out for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2), plus pancreatitis, gallbladder disease and low blood sugar with insulin or a sulfonylurea. These are trial and label findings; review them with your clinician.
The library’s interaction note
It already contains a GLP-1 drug (semaglutide), so it is not combined with another GLP-1, and adding separate cagrilintide or semaglutide doubles up a component. Semaglutide slows stomach emptying, which can affect how oral medicines are absorbed, and with insulin or a sulfonylurea the glucose lowering adds up, raising the risk of low blood sugar (semaglutide labels). Discuss your medicines with your clinician.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the CagriSema reports come from
The library rates the evidence on CagriSema as established: clinical trials or FDA-approved use exist.
Of the library’s 7 research notes on CagriSema, 6 rest on randomized trials and 1 on community reports.
Our 4 study pages on CagriSema: 4 randomized trials.
So CagriSema has controlled trials in people to set its listed effects against.
What our CagriSema study pages report on safety
CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5
Randomized trial, human, 2026: Side effects were reported by 87% of the CagriSema group and 84% of the semaglutide group, mostly stomach and gut problems (53% vs 51%). 10% stopped CagriSema and 6% stopped semaglutide, and one death in the semaglutide group was judged by the investigator as not linked to treatment. In east Asian adults, adding cagrilintide to semaglutide gave 6.5 percentage points more weight loss than semaglutide alone over 68 weeks, with similar rates of side effects.
CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3
Randomized trial, human, 2026: Side effects were reported by 80% of the 2.4 mg arm, 71% of the 1.0 mg arm and 71% on placebo, mostly mild or moderate stomach and gut problems, and no one had severe hypoglycemia (dangerously low blood sugar).
CagriSema: 13.7% weight loss at 68 weeks in REDEFINE 2
Randomized trial, human, 2025: Stomach and gut side effects hit 72.5% on CagriSema and 34.4% on placebo, and most were short-lived and mild or moderate. In people with type 2 diabetes, a large 68-week trial found CagriSema brought clearly more weight loss and better blood sugar than placebo, with stomach and gut side effects common but mostly mild or moderate.
Questions people ask
What are the side effects of CagriSema?
The side effects most commonly reported for CagriSema are nausea, vomiting and diarrhea, among 5 the library lists; the library’s evidence on it includes controlled trials in people.
Do CagriSema’s side effects come from human studies?
The library rates the evidence on CagriSema as established, and the library’s evidence on it includes controlled trials in people.
Which CagriSema side effects are its own?
None: each effect the library lists for CagriSema is listed for at least one other metabolic & GLP-1 compound too.
Does CagriSema interact with other medicines?
The library’s interaction note on CagriSema begins: It already contains a GLP-1 drug (semaglutide), so it is not combined with another GLP-1, and adding separate cagrilintide or semaglutide doubles up a component.